Delivery Order SPE2DB22D3016-SPE2DB26FABC7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $72,115.74 to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This competitively awarded, firm fixed-price contract is scheduled for completion by October 20, 2025, with performance occurring at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency has awarded a delivery order valued at $120,192.80 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of May 15, 2025. The awardee, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency has awarded a delivery order valued at $360,578.40 to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 ml vials. This is a firm fixed-price delivery order with an ultimate completion date of October 21, 2025, issued under a competitive procurement with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ocrevus 300 mg/10 mL vials, valued at $96,154.24 with a firm fixed price structure. The award is non-competitive with no set-aside designation and is scheduled for completion by October 2, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which...
- The Defense Logistics Agency awarded a delivery order valued at $12,019.28 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, scheduled for completion by September 22, 2025. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a $48,077.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on September 19, 2025, with an ultimate completion date of October 10, 2025. This non-competitive delivery order was placed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a $75,998.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials. The contract was competitively awarded without set-aside provisions and is scheduled for completion by November 19, 2025. AmerisourceBergen will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $12,019.28 delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 12, 2025, and performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $120,192.80 by the Defense Logistics Agency on September 18, 2025, for the supply of Ocrevus 300 mg/10 ml vials. This firm fixed-price delivery order, which carries an ultimate completion date of October 9, 2025, represents a competitively awarded contract with no set-aside designation. The contract will be fulfilled from the vendor's Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $360,578.40 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on a firm fixed-price basis. The award, issued on September 24, 2025, with an ultimate completion date of October 16, 2025, represents a competitive procurement with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB26FABC7Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $53,535.55 for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed price, competitively awarded contract with no set-aside designation. The delivery order is expected to be completed by November 25, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor contract valued at $999,999,999 and extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The company's extensive federal contract portfolio with the Defense Logistics Agency demonstrates its capability to supply a wide range of pharmaceutical products and medical supplies across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Ocrevus, a specialty medication used in the treatment of multiple sclerosis, reflects the company's role in delivering critical neurological treatments as part of the broader DLA pharmaceutical support mission.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $53.5k | 11/3/25 |